A Phase 3 interventional study of Brexpiprazole, OPC-34712 in Agitation Associated With, Alzheimer's Disease and Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 71 sites in 9 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 9th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 265 across the 12 interventional studies, 450 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
1 of the studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06875986Otsuka Pharmaceutical Co., Ltd.REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type
Behavioral symptoms, such as agitation, are core features in subjects with Alzheimer's disease and related dementias and develop in the majority of dementia subjects. The presence of agitation in subjects with Alzheimer's disease places a significant burden not only on subjects and their caregivers but also on the healthcare system.
This is a trial designed to assess the safety and efficacy of flexible dosing of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer's type. The trial consists of a 12-week double-blind treatment period with a 30-day follow-up. The trial population will include male and female subjects between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the subject is not living alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching Placebo Once-Daily
Drug: Brexpiprazole, OPC-34712
Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
Drug: Brexpiprazole, OPC-34712
Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score
The CMAI is widely used in clinical research for evaluation of agitation associated with Alzheimer's dementia, with reliability and validity in both institutionalized and noninstitutionalized participants. It consists of 29 items, all rated on a 1 to 7 scale (1=Never and 7=Several times in an hour), with 1 being the "best" rating and 7 being the "worst" rating. The total score is the sum of ratings for all 29 items. The possible total scores range from 29 to 203. The total score will be unevaluable if less than 24 of the 29 items are recorded. If 24 to 28 of the 29 items are recorded, the total score will be the mean of the recorded items multiplied by 29 and rounded to the first decimal place. The mean change from baseline (Day 0) to week 12 in the CMAI total score is reported. Statistical comparison of interest was brexpiprazole flexible dose versus placebo, analyzed using a mixed-effect model repeated measure approach. A decrease in score indicates improvement in symptoms.
Time frame: From screening to week 12/early termination
Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation
The severity of agitation for each participant was rated using the CGI-S. The investigator (or designee) answered the following question: "Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) was the participant at the observation period?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale (1-7). The primary analysis used a mixed-effect model repeated measure approach.
Time frame: From screening to week 12/early termination
The trial was conducted at 62 sites in 9 countries: Bulgaria, Canada, Finland, France, Russia, Slovenia, Ukraine, the United Kingdom (UK), and the United States (US) and 270 participants were randomized. The date of the first ICF signed by a participant in this trial was 28 October 2013 and the date of the last trial observation was 30 March 2017.
| Milestone | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) |
|---|---|---|
| Started | 133 | 137 |
| Completed | 117 | 121 |
| Not completed | 16 | 16 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 9 | 2 |
| Withdrew: Met withdrawal criteria | 0 | 4 |
| Withdrew: Withdrawn by the investigator | 1 | 4 |
| Withdrew: Withdrawal by participant | 5 | 5 |
The CMAI is widely used in clinical research for evaluation of agitation associated with Alzheimer's dementia, with reliability and validity in both institutionalized and noninstitutionalized participants. It consists of 29 items, all rated on a 1 to 7 scale (1=Never and 7=Several times in an hour), with 1 being the "best" rating and 7 being the "worst" rating. The total score is the sum of ratings for all 29 items. The possible total scores range from 29 to 203. The total score will be unevaluable if less than 24 of the 29 items are recorded. If 24 to 28 of the 29 items are recorded, the total score will be the mean of the recorded items multiplied by 29 and rounded to the first decimal place. The mean change from baseline (Day 0) to week 12 in the CMAI total score is reported. Statistical comparison of interest was brexpiprazole flexible dose versus placebo, analyzed using a mixed-effect model repeated measure approach. A decrease in score indicates improvement in symptoms.
| units on a scale | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) |
|---|---|---|
| Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score | -18.9 ± 1.17 | -16.5 ± 1.13 |
The severity of agitation for each participant was rated using the CGI-S. The investigator (or designee) answered the following question: "Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) was the participant at the observation period?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale (1-7). The primary analysis used a mixed-effect model repeated measure approach.
| units on a scale | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) |
|---|---|---|
| Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation | 4.54 ± 0.77 | 4.51 ± 0.74 |
Collected over Through the trial: From screening to Week 12 and 30 (+2) days follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | 0/132 (0%) | 7/132 (5.3%) | 24/132 (18.2%) |
| Placebo (Flexible Dose Range 0.5 to 2 mg/Day) | 1/137 (0.7%) | 6/137 (4.4%) | 29/137 (21.2%) |
| Event | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) |
|---|---|---|
| SeizureNervous system disorders | 2/132 | 0/137 |
| Non-Cardiac Chest PainGeneral disorders | 1/132 | 0/137 |
| PneumoniaInfections and infestations | 1/132 | 1/137 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/132 | 0/137 |
| Loss of consciousnessNervous system disorders | 1/132 | 0/137 |
| PresyncopeNervous system disorders | 1/132 | 0/137 |
| Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders | 1/132 | 0/137 |
| Hypertensive crisisVascular disorders | 1/132 | 0/137 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/132 | 1/137 |
| Femur FractureInjury, poisoning and procedural complications | 0/132 | 1/137 |
| Event | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) |
|---|---|---|
| HeadacheNervous system disorders | 10/132 | 17/137 |
| SomnolenceNervous system disorders | 8/132 | 5/137 |
| DizzinessNervous system disorders | 6/132 | 7/137 |
All participants who were randomized into this trial. Participants were considered randomized when they were assigned a treatment number by interactive voice response system (IVRS) at the end of screening period. A participant who received trial treatment outside of the IVRS was not considered randomized, but safety was reported.
| Age, Customized(Participants) | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) | Total |
|---|---|---|---|
| <65 years | 24 | 19 | 43 |
| >=65 <75 years | 46 | 49 | 95 |
| >=75 years | 63 | 69 | 132 |
| Sex: Female, Male(Participants) | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) | Total |
|---|---|---|---|
| Female | 82 | 88 | 170 |
| Male | 51 | 49 | 100 |
| Race (NIH/OMB)(Participants) | Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) | Placebo (Flexible Dose Range 0.5 to 2 mg/Day) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 9 |
| White | 128 | 129 | 257 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Sep 2013 to primary completion in Mar 2017, 42 months.
Results were first posted in Jul 2020, 3 years 4 months after primary completion. A results delay was requested in May 2018.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 42 months is close to that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →